Trump Announces Generic Drug Tariffs Rising Up To 200%

Trump Introduces New Tariff Framework For Imported Generic Drugs

On July 21 local time, U.S. President Donald Trump announced the latest tariff policy for imported generic drugs through social media, introducing differentiated tariff measures designed to encourage global generic drug production capacity to move back to the United States.

According to the released policy details, all generic drugs imported into the United States will continue to benefit from zero tariffs for the next two years starting from August 1, 2026. After the two-year period ends, related products will face a 100% tariff for one year. Following that period, tariffs will further increase to 200%.

New Tariffs Aim To Encourage Domestic Generic Drug Manufacturing

Trump stated that the core objective of the new policy is to use tariff incentives and penalties to encourage overseas generic pharmaceutical companies to establish production facilities in the United States and bring the entire generic drug supply chain back to domestic production.

The policy introduces a compliance mechanism requiring pharmaceutical companies to complete the construction of U.S.-based manufacturing facilities and supporting equipment within the specified timeframe. Companies that fail to meet these requirements will face significant tariff penalties in accordance with the policy.

Policy Targets Imported Generic Drugs Only

The newly announced tariff measures apply exclusively to imported generic drugs. The U.S. government stated that existing policies targeting patented drugs, branded medicines, and innovative drugs have achieved strong results and will continue to be maintained in order to support a stable environment for domestic pharmaceutical innovation.

Global Generic Drug Supply Chains Face Potential Reshaping

Industry analysts noted that the implementation of the tariff policy could reshape the U.S. generic drug import landscape, creating significant impacts on overseas expansion strategies, production capacity planning, and cost structures of global generic drug exporters.

The policy may also gradually transform the structure of the U.S. generic drug supply chain as pharmaceutical companies reassess their manufacturing strategies and international production networks.